[go: up one dir, main page]

CN109311812A - 作为c-MET抑制剂的吡啶酮类化合物 - Google Patents

作为c-MET抑制剂的吡啶酮类化合物 Download PDF

Info

Publication number
CN109311812A
CN109311812A CN201780036464.XA CN201780036464A CN109311812A CN 109311812 A CN109311812 A CN 109311812A CN 201780036464 A CN201780036464 A CN 201780036464A CN 109311812 A CN109311812 A CN 109311812A
Authority
CN
China
Prior art keywords
pyridones
met inhibitors
inhibitors
met
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780036464.XA
Other languages
English (en)
Other versions
CN109311812B (zh
Inventor
徐雄彬
李刚
丁照中
胡利红
胡国平
黎健
陈曙辉
池志刚
王坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Guangsheng Zhonglin Biotechnology Co.,Ltd.
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62024383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109311812(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of CN109311812A publication Critical patent/CN109311812A/zh
Application granted granted Critical
Publication of CN109311812B publication Critical patent/CN109311812B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明公开了一类作为c‑MET抑制剂的吡啶酮类化合物，具体公开了式(Ⅰ)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201780036464.XA 2016-10-27 2017-10-27 作为c-MET抑制剂的吡啶酮类化合物 Active CN109311812B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610954377 2016-10-27
CN201610954377X 2016-10-27
PCT/CN2017/107964 WO2018077227A1 (zh) 2016-10-27 2017-10-27 作为c-MET抑制剂的吡啶酮类化合物

Publications (2)

Publication Number Publication Date
CN109311812A true CN109311812A (zh) 2019-02-05
CN109311812B CN109311812B (zh) 2020-03-17

Family

ID=62024383

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780036464.XA Active CN109311812B (zh) 2016-10-27 2017-10-27 作为c-MET抑制剂的吡啶酮类化合物

Country Status (28)

Country Link
US (1) US10501443B2 (zh)
EP (1) EP3533787B1 (zh)
JP (1) JP6719679B2 (zh)
KR (1) KR102070748B1 (zh)
CN (1) CN109311812B (zh)
AU (1) AU2017348810B2 (zh)
BR (1) BR112019008415B1 (zh)
CA (1) CA3041164C (zh)
CO (1) CO2019005165A2 (zh)
DK (1) DK3533787T3 (zh)
EA (1) EA038108B1 (zh)
ES (1) ES2835301T3 (zh)
HR (1) HRP20201985T1 (zh)
HU (1) HUE051734T2 (zh)
IL (1) IL266126B (zh)
LT (1) LT3533787T (zh)
MX (1) MX374439B (zh)
MY (1) MY189557A (zh)
PE (1) PE20190912A1 (zh)
PH (1) PH12019500875B1 (zh)
PL (1) PL3533787T3 (zh)
PT (1) PT3533787T (zh)
RS (1) RS61126B1 (zh)
SG (1) SG11201903801YA (zh)
SI (1) SI3533787T1 (zh)
UA (1) UA122737C2 (zh)
WO (1) WO2018077227A1 (zh)
ZA (1) ZA201903074B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004801A (zh) * 2018-04-26 2020-11-27 福建广生堂药业股份有限公司 一种c-MET 抑制剂的晶型及其盐型和制备方法
CN116171156A (zh) * 2020-07-31 2023-05-26 南京明德新药研发有限公司 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020156453A1 (zh) * 2019-02-01 2020-08-06 南京明德新药研发有限公司 作为c-Met抑制剂的含嘧啶基团的三并环类化合物
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
US20240277711A1 (en) 2021-06-04 2024-08-22 Merck Patent Gmbh Compounds for the treatment of glioblastoma
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743241A (zh) * 2007-07-12 2010-06-16 默克专利有限公司 哒嗪酮衍生物
CN104144925A (zh) * 2011-10-17 2014-11-12 拜耳知识产权有限责任公司 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586418B2 (en) 2000-06-29 2003-07-01 Bristol-Myers Squibb Company Thrombin or factor Xa inhibitors
JPWO2005085200A1 (ja) * 2004-03-05 2008-01-17 萬有製薬株式会社 ピリドン誘導体
AU2008219166B2 (en) * 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
EP2827872A1 (en) * 2012-03-19 2015-01-28 Merck Patent GmbH Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
EP2906294B1 (en) * 2012-10-11 2018-04-18 Merck Patent GmbH Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor
ES2945865T3 (es) 2014-12-11 2023-07-10 Merck Patent Gmbh Combinación de un derivado de 6-oxo-1,6-dihidropiridazina que tiene actividad anticancerígena con un derivado de quinazolina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743241A (zh) * 2007-07-12 2010-06-16 默克专利有限公司 哒嗪酮衍生物
CN104144925A (zh) * 2011-10-17 2014-11-12 拜耳知识产权有限责任公司 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004801A (zh) * 2018-04-26 2020-11-27 福建广生堂药业股份有限公司 一种c-MET 抑制剂的晶型及其盐型和制备方法
AU2019260240B2 (en) * 2018-04-26 2023-05-11 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor
CN112004801B (zh) * 2018-04-26 2023-09-08 福建广生中霖生物科技有限公司 一种c-MET抑制剂的晶型及其盐型和制备方法
CN116171156A (zh) * 2020-07-31 2023-05-26 南京明德新药研发有限公司 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法

Also Published As

Publication number Publication date
HUE051734T2 (hu) 2021-03-29
PT3533787T (pt) 2020-11-20
EP3533787A1 (en) 2019-09-04
ZA201903074B (en) 2020-01-29
UA122737C2 (uk) 2020-12-28
CO2019005165A2 (es) 2019-05-31
RS61126B1 (sr) 2020-12-31
MY189557A (en) 2022-02-16
BR112019008415A2 (pt) 2019-07-09
KR102070748B1 (ko) 2020-01-29
CA3041164A1 (en) 2018-05-03
CN109311812B (zh) 2020-03-17
JP6719679B2 (ja) 2020-07-08
PH12019500875B1 (en) 2024-03-01
MX374439B (es) 2025-03-06
KR20190058678A (ko) 2019-05-29
IL266126A (en) 2019-06-30
MX2019004626A (es) 2019-11-08
WO2018077227A1 (zh) 2018-05-03
IL266126B (en) 2020-07-30
NZ753020A (en) 2021-08-27
PE20190912A1 (es) 2019-06-26
PH12019500875A1 (en) 2019-06-17
US20190248763A1 (en) 2019-08-15
SG11201903801YA (en) 2019-05-30
EA201990952A1 (ru) 2019-11-29
EP3533787B1 (en) 2020-09-30
CA3041164C (en) 2019-12-17
LT3533787T (lt) 2020-11-25
EA038108B1 (ru) 2021-07-07
PL3533787T3 (pl) 2021-03-08
US10501443B2 (en) 2019-12-10
HRP20201985T1 (hr) 2021-02-05
AU2017348810A1 (en) 2019-05-23
ES2835301T3 (es) 2021-06-22
AU2017348810B2 (en) 2020-05-07
EP3533787A4 (en) 2019-11-13
BR112019008415B1 (pt) 2020-09-29
JP2019535806A (ja) 2019-12-12
SI3533787T1 (sl) 2021-01-29
DK3533787T3 (da) 2020-11-30

Similar Documents

Publication Publication Date Title
CN109311812A (zh) 作为c-MET抑制剂的吡啶酮类化合物
LT3577110T (lt) 8-oksetan-3-il-3,8-diazabiciklo[3.2.1]oktan-3-ilo pakeistieji junginiai, kaip živ inhibitoriai
CN115298174A (zh) 嘧啶并杂环类化合物及其应用
JP2018024670A5 (zh)
JP2015522045A5 (zh)
PH12016501813B1 (en) 1,3-benzodioxole derivative
HK1252159A1 (zh) [4-(1，3，3-三甲基-2-氧代-3，4-二氫-1h-喹喔啉-7-基)苯氧基]乙基氧基化合物或其鹽
JP2015528502A5 (zh)
JP2013173781A5 (zh)
JP2015513557A5 (zh)
CN111712499A (zh) 一种atr抑制剂及其应用
JP2019089762A5 (zh)
JP2018150298A5 (zh)
CN110099900A (zh) 针对Smoothened突变株的刺猬通路抑制剂
MX2018001517A (es) Derivados sustituidos de guanidina.
DK3844161T3 (da) Heteroaromatiske forbindelser som vanininhibitorer.
EP3768663A4 (en) NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES, OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS THEREOF
PH12018501709A1 (en) Naphthridinedione derivatives
DK3386994T3 (da) 4,6-di-(o-thiophosphat)-inositol-1,2,3,5-tetra-o-sulfat mod c. difficile-infektion
WO2015022265A3 (en) Cyclobutyl carboxamides as nematicides
CN112004801A (zh) 一种c-MET 抑制剂的晶型及其盐型和制备方法
CN113993867A (zh) 作为fgfr和vegfr双重抑制剂的并环类化合物
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.
JP2018519528A5 (zh)
EA201892449A1 (ru) Конденсированные гетероциклические соединения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 355399 Fuyuan Industrial Zone, Dongyuan Township, Zherong County, Ningde City, Fujian Province

Applicant after: Fujian Cosunter Pharmaceutical Co., Ltd.

Address before: 350003 Block B, Building 10, Software Park B, 89 Software Avenue, Gulou District, Fuzhou City, Fujian Province

Applicant before: Fujian Cosunter Pharmaceutical Co., Ltd.

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002592

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220127

Address after: 355300 building 1-7, Fuyuan Industrial Park, Zherong County, Ningde City, Fujian Province

Patentee after: Fujian Guangsheng Zhonglin Biotechnology Co.,Ltd.

Address before: 355399 Fuyuan Industrial Zone, Dongyuan Township, Zherong County, Ningde City, Fujian Province

Patentee before: FUJIAN COSUNTER PHARMACEUTICAL Co.,Ltd.